Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?

Rodríguez García, Eva; Barrios Barrera, Clara; Soler, María José

doi:http://dx.doi.org/10.1093/ckj/sfx024

Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?

License

Citation

Rodriguez E, Barrios C, Soler MJ. Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?. Clin Kidney J. 2017 Jun;10(3):320-322. DOI: 10.1093/ckj/sfx024

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supporting eculizumab discontinuation, which may be associated with high collateral risks such as loss of renal function, other authors believe that the drug can be safely discontinued with close patient monitoring. In this editorial, we update the pros and cons for eculizumab discontinuation in aHUS.